Initial experience with the Nikkiso centrifugal pump during thoracoabdominal aortic aneurysm repair

Coselli, Joseph S.; LeMaire, Scott A.; Ledesma, Dwayne F.; Ohtsubo, Satoshi; Tayama, Eiki; Nosé, Yukihiko

doi:10.1016/s0741-5214(98)70372-6

Cited by 20 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Passive shunts such as the Gott shunt or the axillofemoral bypass have been successfully used during the past years (2), but are, nowadays, supplanted by the use of left atrial to the distal aortic segment or femoral artery bypass (21,67,(91)(92)(93)(94) or even cardiopulmonary bypass (95-97) through which perfusion pressure and temperature can be regulated. In fact, passive shunts seem to provide suboptimal blood ow and perfusion pressure (<40 mmHg), whereas atriofemoral or femoro-femoral bypasses can adjust the mean distal aortic pressures between 60 and 70 mmHg (98), values which are more likely to maintain a spinal cord perfusion pressure above 40 mmHg (43).…”

Section: Distal Aortic Perfusionmentioning

confidence: 99%

“…The use of a three-way circuit (in ow and out ow cannulas plus four balloon cannulas for visceral perfusion) has been shown to easily afford both goals (3,92). During aortic cross-clamping, perfusion of the distal aorta is provided through an out ow cannula inserted into the aneurysmal middescending thoracic aorta or into the common femoral artery.…”

Section: Distal Aortic Perfusionmentioning

confidence: 99%

See 1 more Smart Citation

Strategies for Spinal Cord Protection during Descending Thoracic and Thoracoabdominal Aortic Surgery: Up-to-date Experimental and Clinical Results - A review

Juvonen

Biancari²,

Rimpiläinen³

et al. 2002

Scandinavian Cardiovascular Journal

View full text Add to dashboard Cite

Section: Distal Aortic Perfusionmentioning

confidence: 99%

Section: Distal Aortic Perfusionmentioning

confidence: 99%

Strategies for Spinal Cord Protection during Descending Thoracic and Thoracoabdominal Aortic Surgery: Up-to-date Experimental and Clinical Results - A review

Juvonen

Biancari²,

Rimpiläinen³

et al. 2002

Scandinavian Cardiovascular Journal

View full text Add to dashboard Cite

“…Clinical application in Japan was initiated in 1993 (27,33). Clinical application in the United States was initiated in 1995 for the Phase I system (FDA model) and in 1998 for the Phase II system (29,34) (Commercial model).…”

Section: The Last 10 Yearsmentioning

confidence: 99%

“…One important issue is that it was necessary to have some time for the conversion of a laboratory type preproduction pump model to a clinically applicable (mass production) system. It took 1 year for a 2 day pump in Japan (26,27) (2 years in the United States) (25,28), 2 years for the 2 week pump in Japan, and possibly 5 years for a permanent pump (26,29). This difficult task was completed in 1 year for the DeBakey VAD system (28,30).…”

Section: The Last 10 Yearsmentioning

confidence: 99%

Development of Rotary Blood Pump Technology: Past, Present, and Future

et al. 2000

Self Cite

View full text Add to dashboard Cite

Even though clinical acceptance of a nonpulsatile blood flow was demonstrated almost 45 years ago, the development of a nonpulsatile blood pump was completely ignored until 20 years ago. In 1979, the first author's group demonstrated that completely pulseless animals did not exhibit any abnormal physiology if 20% higher blood flows were provided to them. However, during the next 10 years (1979-1988), minimum efforts were provided for the development of a nonpulsatile, permanently implantable cardiac prosthesis. In 1989, the first author and his team at Baylor College of Medicine initiated a developmental strategy of various types of nonpulsatile rotary blood pumps, including a 2-day rotary blood pump for cardiopulmonary bypass application, a 2 week pump for ECMO and short-term circulatory assistance, a 2 year pump as a bridge to transplantation, and a permanently implantable cardiac prosthesis. Following the design and developmental strategy established in 1989, successful development of a 2-day pump (the Nikkiso-Fairway cardiopulmonary bypass pump) in 4 years (1989-1993), a 2 week pump (Kyocera gyro G1E3 pump) in 6 years (1992-1998), and a bridge to transplant pump (DeBakey LVAD-an axial flow blood pump) in 10 years (1988-1998) was made. Currently, a permanently implantable centrifugal blood pump development program is successfully completing its initial Phase 1 program of 5 years (1995-2000). Implantation exceeded 9 months without any negative findings. An additional 5 year Phase II program (2000-2005) is expected to complete such a device that will be clinically available.

show abstract

“…[8][9][10] The recent report of our initial experience using the Nikkiso pump for left heart bypass during TAAA repair described excellent pump function that provided sufficient flow for both distal aortic and selective visceral perfusion and successfully prevented permanent spinal cord injury and organ failure in 10 patients. 11 The purpose of this study was to prospectively compare the performance of the Nikkiso and Bio-Medicus pumps for left heart bypass during the repair of extensive TAAAs.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Nikkiso and Bio-Medicus Pumps in Thoracoabdominal Aortic Surgery

Coselli

Ledesma

LeMaire

et al. 1999

Asian Cardiovasc Thorac Ann

Self Cite

View full text Add to dashboard Cite

Left heart bypass reduces the risk of ischemic complications during the repair of extensive thoracoabdominal aortic aneurysms. This prospective study compared the performance of the recently developed Nikkiso centrifugal pump with the wellestablished Bio-Medicus pump during left heart bypass for thoracoabdominal aortic aneurysm surgery. Thirty-five consecutive patients undergoing graft repair of extensive thoracoabdominal aortic aneurysms were prospectively assigned to have left heart bypass using either the Bio-Medicus (in the first 19 patients) or Nikkiso pump (in the next 16 patients). There were no significant differences in pump flow rates or patient hemodynamics between the two groups and there was no evidence of pump malfunction. All patients survived and none developed postoperative coagulopathy, myocardial infarction, or left heart failure. Paraparesis developed in 2 patients in the Nikkiso group (12.5%); there were no neurologic complications in the Bio-Medicus group (p = 0.202). One patient in the Bio-Medicus group developed renal failure (5.3%; p = 1.000 vs. Nikkiso group). Overall, no significant differences were found in the incidence of postoperative complications. Although a small series, this comparison demonstrates that the Nikkiso centrifugal pump is as effective and safe in providing left heart bypass during thoracoabdominal aortic aneurysm repair as the widely-used Bio-Medicus model.

show abstract

Initial experience with the Nikkiso centrifugal pump during thoracoabdominal aortic aneurysm repair

Cited by 20 publications

References 42 publications

Strategies for Spinal Cord Protection during Descending Thoracic and Thoracoabdominal Aortic Surgery: Up-to-date Experimental and Clinical Results - A review

Strategies for Spinal Cord Protection during Descending Thoracic and Thoracoabdominal Aortic Surgery: Up-to-date Experimental and Clinical Results - A review

Development of Rotary Blood Pump Technology: Past, Present, and Future

Comparison of Nikkiso and Bio-Medicus Pumps in Thoracoabdominal Aortic Surgery

Contact Info

Product

Resources

About